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StabilityThe E6 protein from high-risk human papillomaviruses appears necessary for persistence of viral episomes in
cells but the underlyingmechanism is unclear. E6 has many activities, including its ability to bind and degrade
PDZ domain-containing proteins, such as hScrib. However little is known about the role of these interactions
for E6 function and the viral life cycle. We now show that the levels of expression of wild-type E6 are
increased in the presence of hScrib whilst a mutant E6 protein lacking the PDZ-binding motif is found at lower
levels as it is turned over more rapidly by the proteasome. This correlates with an inability of genomes
containing this mutation to be maintained as episomes. These results show that E6 association with certain
PDZ domain-containing proteins can stabilize the levels of E6 expression and provides one explanation as to
how the PDZ-binding capacity of E6 might contribute to genome episomal maintenance.
Crown Copyright © 2011 Published by Elsevier Inc. All rights reserved.Introduction
Papillomaviruses (PV) are small DNA viruses that infect epithelial
tissue and can give rise to hyper-proliferative lesions (reviewed in
Howley and Lowy, 2001). In most cases these lesions are benign but a
small number of papillomaviruses (high-risk types) cause lesions that
may becomemalignant. Probably the most signiﬁcant of these, from a
clinical perspective is HPV16, which is responsible for the majority of
cases of cervical cancer (Walboomers et al., 1999). The life-cycle of
papillomaviruses is tightly linked to the differentiation of the host
epithelium. The virus enters the basal cells, where multiple copies of
the viral genome become established as persistent episomes. These
cells divide, and as they move towards the surface of the epithelium
they differentiate, triggering expression of the different viral proteins
and viral DNA ampliﬁcation (reviewed in Doorbar, 2006).
One of the early HPV genes expressed is E6, giving rise to the multi-
functional E6 protein, and it has been observed that genomes that
express some mutant E6 proteins fail to establish as episomes within
cells (Park and Androphy, 2002; Thomas et al., 1999). The reasons for
this are unclear; however the E6protein is known tohave amultitude of
binding partners and activities, and its effects on the virus life-cycle and
malignant progression are many and complex. Proposed roles of the E6
protein in the virus life-cycle include inhibition of apoptosis induced by).
s, Health Protection Agency,
11 Published by Elsevier Inc. All rigthe expression of the HPV E7 protein and also facilitation of viral DNA
ampliﬁcation in the upper layers (Wang et al., 2009). The most well-
studied interaction of HPV E6 with a cellular protein is that of its
association with p53, which results in the ubiquitin-mediated degra-
dation of p53 by the proteasome (Scheffner et al., 1990). The E6-
facilitated degradation of p53 appears to have a role in genome
maintenance (Park and Androphy, 2002; Thomas et al., 1999), but
whether this activity is strictly necessary and sufﬁcient for establish-
ment of episomes is uncertain. E6 mediates degradation of p53 by
associating with E6AP, a cellular ubiquitin ligase, and changing its
substrate speciﬁcity so that it now targets p53 (Huibregtse et al., 1991).
E6AP is also implicated in the ability of E6 to activate the transcription of
the catalytic subunit of telomerase, hTERT (Liu et al., 2005), and this
activity is thought to be responsible for E6's ability to immortalize cells.
Interestingly, it has recently been shown that E6AP also functions to
protect the HPV16 and 18 E6 proteins from proteasomal degradation,
thereby increasing their stability (Tomaic et al., 2009). Crucially this
suggests that some of the activities of E6 that had previously been
attributed to the catalytic activity of E6AP could instead be dependent
on E6AP only to provide sufﬁcient levels of E6.
The carboxy terminus of all the high-risk HPV type E6 proteins
contains amotif (X―(S/T)―X―(V/I/L)―COOH) that is able to recognize
and bind to PDZ domains (reviewed in Thomas et al., 2008). PDZ
domains are structural domains composed of 80–90 amino acids that
bind to short stretches on the C-terminus of other proteins. Again
interaction of E6 with the PDZ domain-containing proteins can result in
their degradation. In particular, the association between high-risk E6
proteins and a sub-category of PDZ domain-containing proteins that arehts reserved.
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signiﬁcance (reviewed in Pim and Banks, 2010). These proteins include
Dlg, hScrib, MAGI and many others, and they are involved in activities
such as tight junction assembly, the establishment of apicobasal polarity
and cell cycle progression (Latorre et al., 2005; Nagasaka et al., 2006).
The speciﬁcity for each of these PDZ domain-containing proteins
depends on the particular E6 protein involved (Thomas et al., 2001),
and on the localization and modiﬁcation of the PDZ domain-containing
proteins. Importantly, the ability to bind PDZ domain-containing
proteins appears to be an activity characteristic of many high-risk HPV
types. Most low-risk E6 proteins do not have a PDZ bindingmotif (PBM)
and loss of PDZ domain-containing proteins appears to correlate with
malignant progression. For these reasons the potential role of the
association between high-risk E6 proteins and PDZ domains has been
proposed as being important for the ability of high-risk viruses to
transform cells. However the role of the interaction between PDZ
domain-containing proteins and HPV E6 proteins in productive virus
life-cycles is less well understood. In HPV type 31 it was found that
mutation of the E6 PBM resulted in changes to the growth and
morphological differentiation of cells and to the viral copy number
(Lee and Laimins, 2004). However, themechanism for how themutation
caused these effects was not investigated.
Herewe show that loss of the capacity of HPV16 E6 to interact with
PDZ domain-containing proteins results in enhanced proteasomal
degradation of the E6 protein. Stabilization of E6 is dependent on its
PBM and on the PDZ domains of, for example, hScrib. We also ﬁnd that
failure of a mutant E6 to be stabilized by PDZ domain-containing
proteins correlates with the inability of genomes carrying this
mutation to establish and maintain as episomes within cells.
Results
HPV16 E6 levels are increased by hScrib in a PDZ-dependent manner
Previous studies have shown that E6-PDZ targeting is important for
several aspects of E6 biology (for review see Thomas et al., 2008).
However little is known about its role in the viral life cycle or with
respect to E6 function itself, the latter point being particularly relevant
in the light of recent studies showing a role for E6AP in regulating E6
stability (Tomaic et al., 2009). Since a major PDZ interacting partner of
HPV16 E6 is hScrib (Thomas et al., 2005) we decided to investigate
whether the hScrib–E6 interaction could in any way affect E6 levels of
expression. To do this, a plasmid that expresses wild-type E6 was co-
transfected with either an HA-Scrib-expressing plasmid or control
pcDNA plasmid into NIKS cells. We chose NIKS cells as these cells can
support the HPV16 virus life-cycle (Lambert et al., 2005) and are
therefore a good model system to work with when analyzing potential
functions of HPV16 proteins during productive infection, rather than
during cancer progression. The levels of E6 were analyzed by Western
blot (Fig. 1A). The presence of hScrib signiﬁcantly increased the levels ofFig. 1. E6 levels are increased by an interaction between E6 and hScrib. Normal
immortalized human keratinocytes (NIKS) were transiently co-transfected with
plasmids that express wild-type HPV16 E6 protein or a mutant lacking the PBM
(E6WT and E6ΔPBM respectively), or HA-tagged HPV11 E6 protein (HA-11E6), and HA-
tagged wild-type hScrib protein or a mutant lacking the PDZ region (HA-Scrib and HA-
ScribΔPDZ respectively). A) E6WT co-transfected with either HA-Scrib or control
pcDNA plasmid. B) E6ΔPBM co-transfected with either HA-Scrib or control pcDNA
plasmid. C) E6WT co-transfected with either HA-ScribΔPDZ or control pcDNA plasmid.
D) HA-Scrib co-transfected with E6WT, E6ΔPBM or control pMV11 plasmid. E) E6WT or
E6ΔPBM co-transfected with control pcDNA plasmid. F) HA-11E6 or control pMV11
plasmid co-transfected with either HA-Scrib or control pcDNA plasmid. The trans-
fections were spiked with a plasmid that expresses β-gal. Total cell extracts were
obtained from cells 48 h post-transfection and Western blotted where appropriate for
E6 proteins, HA-Scrib, β-gal and as loading controls HSP70 or histone 2 B (H2B). Levels
of E6 were assessed using ImageJ software. Cells were transfected in triplicate and bar
charts show the mean E6 protein levels (in arbitrary units)+the standard deviation,
relative to the loading controls. Unpaired T-tests were used to compare the E6 levels
and p values are given above the charts.E6 protein, suggesting that binding of E6 to hScrib may increase the
stability of E6. To assesswhether the increase in levels of E6was related
to binding to hScrib, we repeated the experiment using an E6 mutant
Fig. 2. The higher E6WT protein levels are dependent on hScrib, and do not result from
increased levels of transcript. NIKS cells were transiently co-transfected with plasmids
that express E6WT or E6ΔPBM, and HA-Scrib. A) At 48 h post-transfection, total cell
lysates were obtained and Western blotted for E6, HA and β-gal, and as a loading
control, HSP70. B) RNA was extracted from cells at 48 h post-transfection and
converted to cDNA. Transcript levels were assessed using primers to E6 and cellular
β-actin. Cells were transfected in triplicate and bar charts show the mean E6 transcript
level (in arbitrary units)+the standard deviation, relative to the β-actin levels. An
unpaired T-test was used to compare the E6 transcript levels and the p value is given
above the chart. C) Extracts were Western blotted for E6 proteins using an antibody to
the N-terminus of E6, and as a loading control, HSP70. D) HeLa cells were transfected
with siRNA to hScrib or as controls E6/E7 or luciferase (Luc). At 72 h post-transfection
total cell extracts were analyzed by Western blotting using antibodies to 18E6, hScrib
and as a loading control, α-actinin. The cells were independently transfected twice and
the bar chart shows themean level of 18E6, normalized to the level present with control
luciferase siRNA,±the range.
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PDZ domains (Fig. 1C). Co-expression of wild-typeHA-ScribwithΔPBM
mutant E6 did not result in a signiﬁcant change in E6 levels compared to
that in the absence of HA-Scrib. Similarly co-expression of wild-type E6
with the PDZ domain mutant of hScrib did not alter E6 levels. Together
these data suggest that an interaction between the E6 PBM and the PDZ
domains of hScrib increases the stability of E6. To test whether the level
of E6ΔPBM protein was indeed lower than that of wild-type E6 protein
in the presence of HA-Scrib, the co-transfection experiment was
repeated and the levels of thewild-type and E6ΔPBMprotein compared
(Fig. 1D). As expected the levels of E6ΔPBM were signiﬁcantly lower
thanwild-type E6 levels. We observed similar results when using other
cell lines in addition to NIKS (data not shown). Of course, in addition to
the HA-Scrib that we co-transfect, the NIKS cells also contain
endogenous hScrib and we wanted to determine whether this would
also have a similar effect on E6 levels. To test this we repeated the
experiment but without co-transfecting HA-Scrib (Fig. 1E). Under these
conditions we did not see a signiﬁcant difference between the levels of
wild-type and E6ΔPBM protein. However, since E6 is being expressed
from a CMV promoter it seems likely that a potential role for the
endogenous hScrib is masked by the very high levels of E6 expression.
Indeed, we have found, using qPCR, that the level of E6 transcripts is
100× higher from our CMV promoter than from the HPV16 genome
(data not shown). As the levels of E6 expressed fromgenomes are below
the limits of easy detection, we decided to continue working with the
CMV-derived E6 and co-transfection with HA-Scrib. Since the low risk
HPV11 E6 lacks PDZ binding potential we proceeded to investigate
whether hScrib could similarly affect the levels of HPV11 E6 expression.
The results in Fig. 1F demonstrate that hScrib has no effect on HPV11 E6
expression levels, consistent with their inability to interact (Nakagawa
and Huibregtse, 2000).
Differences in E6 levels are due to protein stability
To address what is causing the difference in levels between the
wild-type and E6ΔPBMmutant proteins, we ﬁrst checked the levels of
β-galactosidase expressed from a co-transfected plasmid and these
showed the transfection efﬁciencies to be the same (Fig. 2A). To further
support this we checked that protein levels were not varying because of
differences at the level of transcription. The wild-type and E6ΔPBM
plasmidswere co-transfectedwithHA-Scrib plasmid intoNIKS cells. The
cellswereharvestedat48 handRT-qPCRwasused to assess the levels of
E6 transcripts and these were normalized to the levels of β-actin
transcripts (Fig. 2B). The levels of wild-type and E6ΔPBM mutant
transcripts are not statistically signiﬁcantly different and if anything, the
E6ΔPBMmutant transcript levels appear higher. This indicates that the
reduced levels of the E6ΔPBM protein are not due to reduced
transcription of the E6ΔPBM mutant gene. To test whether using an
antibody to the C-terminal half of E6 was causing the apparent
differences in levels of thewild-type and E6ΔPBMproteins,we repeated
the blots using anantibody that recognizes anepitope in theN-terminus
of E6 (Fig. 2C). Again, the levels ofwild-type E6were signiﬁcantly higher
than the levels of the E6ΔPBM mutant, suggesting that the effect is not
simply due to antibody afﬁnities. To support that it was the presence of
hScrib that was responsible for the elevated levels of wild-type E6, we
decided to knock-down hScrib in cells that express endogenous E6. We
were unable to achieve adequately high efﬁciency transfection of siRNA
into NIKS cells (data not shown), but were able to substantially knock-
downhScrib inHeLa cells.When these cellswere transfectedwith siRNA
tohScrib, the levels of E6were greatly reduced (Fig. 2D), suggesting that
again in this system, hScrib is promoting higher levels of E6.
To determine whether loss of E6 in the absence of an interaction
with hScrib was due to increased protein turnover the wild-type and
E6ΔPBMmutant plasmids were co-transfected with HA-Scrib plasmid
into NIKS cells. After 46 h the cells were treated with the protein
synthesis inhibitor cycloheximide (Fig. 3A). As can be seen, the rate ofloss of the E6ΔPBM protein is greater than that of the wild-type
showing that the mutant is less stable than the wild-type in the
presence of ectopically expressed hScrib. Given the structure of E6
(Nomine et al., 2006) it seems unlikely that the mutation itself is
having any major effect on the structural integrity of the protein;
therefore we hypothesize that the PBM on the wild-type protein is
actively involved in stabilizing the protein. Since E6 is known to be
degraded by the proteasome (Kehmeier et al., 2002; Stewart et al.,
2004), the PBM may protect certain pools of E6 from proteasomal
degradation. To test this the wild-type and E6ΔPBM plasmids were
co-transfected with HA-Scrib plasmid into NIKS cells. At 46 h post-
transfection, the cells were treated for 2 h with the proteasome
inhibitor, MG132 (Fig. 3B). The levels of wild-type E6 protein in the
presence and absence of inhibitor are not statistically signiﬁcantly
different. In contrast, the levels of the E6ΔPBM protein are
signiﬁcantly increased in the presence of MG132, with the majority
of this protein being degraded by the proteasome in the absence of the
inhibitor. Together these data suggest that wild-type E6 protein is
protected from proteasomal degradation by virtue of its PBM. Given
that the difference in protein levels between transiently transfected
wild-type and E6ΔPBM is observed when HA-Scrib is co-transfected
but not in its absence (Fig. 1E), it seems reasonable to conclude that
the stabilization effect results from an interaction between E6 and
hScrib, rather than indirect effects of loss of the PBM.
Other PDZ domain-containing proteins, in addition to hScrib, can
stabilize E6
In addition to hScrib, other PDZ domain-containing proteins
including Dlg (the human homologue of the Drosophila tumor
suppressor protein, dlg, found localized with hScrib at adherens
junctions) and MAGI-1 (localized at tight junctions) are also bound
and directed for degradation by HPV E6 (Gardiol et al., 1999;
Glaunsinger et al., 2000; Kiyono et al., 1997). The ability of E6 to
bind and degrade these PDZ domain-containing proteins appears to
Fig. 4. Multiple PDZ domain-containing proteins can stabilize E6. A) NIKS or B) 293T
cells were transiently transfected with plasmids that express HA-tagged Dlg (HA-Dlg)
or FLAG-tagged MAGI (FLAG-MAGI), and E6WT or E6ΔPBM. Total cell extracts were
obtained from cells 2 days post-transfection and Western blotted for E6, HA or FLAG,
and as a loading control histone 2B (H2B) or HSP70. Levels of E6 were assessed using
ImageJ software. Cells were transfected in triplicate and bar charts show the mean E6
levels (in arbitrary units)+the standard deviation, relative to loading controls.
Unpaired T-tests were used to compare the E6 protein levels and p values are given
above the charts.
Fig. 3. The ΔPBM mutation reduces E6 levels by decreasing the protein's stability. NIKS
cells were transiently co-transfected with plasmids that express E6WT or E6ΔPBM, and
HA-Scrib. A) At 48 h post-transfection cells were treated with 50 μg ml−1 cyclohex-
imide or DMSO for 60 or 120 min. Total cell extracts were analyzed by Western blot.
Levels of E6 were assessed using ImageJ software. Cells were transfected in duplicate
and bar charts show the mean E6 protein levels relative to the corresponding wild-type
or E6ΔPBM level at time 0+the standard deviation. An unpaired T-test was used to
compare the E6 protein levels, at 120 min, p=0.032. B) At 46 h post-transfection, cells
were treated for a further 2 h with the proteasome inhibitor MG132 or DMSO. Total cell
extracts were analyzed by Western blotting using antibodies to E6 and HA, and as a
loading control, HSP70. Levels of E6 were assessed using ImageJ software. Cells were
transfected in triplicate and bar charts show the mean E6 protein levels (in arbitrary
units)+the standard deviation. Paired T-tests were used to compare the E6 protein
levels and p values are given above the charts.
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preferring Dlg and MAGI-1 (Kranjec and Banks, 2010; Thomas et al.,
2005). To determine whether other PDZ domain-containing proteins
in addition to hScrib can affect E6 levels, the wild-type E6 and
E6ΔPBM mutant plasmids were co-transfected with plasmids that
express FLAG-MAGI or HA-Dlg into NIKS cells, and the levels of E6
proteins were assessed by Western blot (Fig. 4A). As with HA-Scrib,
the level of wild-type E6 was higher than the ΔPBM mutant in the
presence of both FLAG-MAGI and HA-Dlg, suggesting that these two
PDZ domain containing proteins could similarly affect the levels of E6
expression in a PBM dependent manner. Since the FLAG-MAGI and
HA-Dlg proteins could not actually be detected in the transfected NIKS
cells, expression was veriﬁed by transfection into 293T cells (Fig. 4B).
Genomes lacking E6 proteins that can bind to PDZ domains show
low-level E6 expression and a failure to maintain as episomes in NIKS cells
Having shown that hScrib can regulate E6 levels of expression,
both in cervical cancer derived cell lines and under conditions of over-
expression we were keen to assess whether the wild type andE6ΔPBM mutant proteins were similarly affected when expressed
from the HPV16 genome and how this might impact upon the virus
life cycle (Fig. 5). Initial attempts at detecting E6 protein expressed in
the total cell populations from genomes were unsuccessful (data not
shown), and this is not surprising given our previous observation that
E6 transcript levels from genomes are over 100× lower than from the
CMV promoter. This problem was further exacerbated by the
relatively low efﬁciency of transfection into NIKS cells and the need
to analyze the E6 levels very early after transfection, i.e. without
prolonged selection, to prevent downstream effects indirectly
affecting the E6 levels. To overcome this issue, the wild-type and
E6ΔPBM genomes were co-transfected with a plasmid that expresses
GFP into the NIKS cells. After 48 h FACS was used to identify GFP-
expressing cells, thereby enriching for the cells containing HPV
genomes. The levels of E6 proteins were compared in populations
transfected with wild-type and E6ΔPBM mutant genomes, and again
it was found that the levels of the E6ΔPBM protein were much lower
than those of the wild-type (Fig. 5A). To conﬁrm that the differences
in protein were not due to differences in the levels of E6 transcripts
these were assessed using RT-qPCR (Fig. 5B). The level of E6
transcripts is not signiﬁcantly different between the wild-type and
E6ΔPBM genomes, implying that the genomes are present at similar
levels and that the difference in protein levels does not arise from
differential transcription. This suggests that, when E6 is expressed
from HPV genomes, the endogenous PDZ domain-containing proteins
may stabilize the E6 protein via interaction with E6's PBM, as seen in
the experiments carried out using recombinant expression plasmids.
Having conﬁrmed that the E6 levels were lower in the E6ΔPBM
genome populations than in the wild-type populations, we then
assessed whether the difference was sufﬁcient to disrupt aspects of
the viral life-cycle. In order to have a productive life-cycle, it is ﬁrst
necessary for the viral genomes to become established as episomes in
the host cell. It has already been shown for HPV31 E6, that mutations
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2004), but in that study, it was not possible to directly assess the levels
of the wild-type andmutant E6 proteins expressed from the genomes.
We hypothesized that the lack of E6 stability we observe with the HPV
type 16 E6ΔPBM mutant protein could also cause a reduction in viral
copy number in cells transfected with the HPV16 genomes. First we
conﬁrmed using a transient replication assay that both the wild-type
and E6ΔPBM genomes were able to be replicated within cells, i.e. that
the ΔPBM mutation did not compromise other aspects of the
plasmid's capacity to express and interact with the viral and cellular
replication proteins. To do this NIKS cells were transfected with the
genomes or a control plasmid that has the E4 open reading frame
but no eukaryotic origin of replication or promoter. Four days post-transfection the proportion of replicated DNA (distinguishable from
input DNA by virtue of its resistance to the restriction enzyme Dpn I)
was quantiﬁed by qPCR using primers against E4 (Fig. 5C). Both
genomes were found to replicate in this assay. To assess the ability of
the wild-type and E6ΔPBM genomes to establish as episomes, the
genomes were co-transfected with a blasticidin resistance plasmid
into NIKS and populations were selected with blasticidin for 4 days.
The cells were then passaged onto fresh feeders in the absence of
blasticidin, and these cells were denoted passage one (P1). The DNA
was extracted from the cells over a number of passages and the mean
genome copy number per cell was assessed by qPCR (Fig. 5D). The
copy number appears to bemuch lower in the 16E6ΔPBM populations
than in the 16WT populations. Interestingly, the copy number of the
16E6ΔPBMmutant populations does seem to slightly increase at later
passages. To further assess the populations, the status of their
genomes was assessed by Southern blot with a view to determining
whether they were episomal or integrated (Fig. 5E). The extracted
DNA was cut with restriction enzymes that either do not cut, or cut
once, the HPV16 genome. From this it was clear that the wild-type
DNA was predominantly episomal, whilst the 16E6ΔPBM mutant
DNA, although very difﬁcult to detect, was predominantly integrated.
To determine whether the inability to maintain episomes might be
mediated by lower levels of E6 failing to degrade p53, the levels of p53
were assessed in the populations of transfected and FACS-sorted cells.
It was found that the extent of p53 degradation was similar in the
wild-type and E6ΔPBM mutant genome populations, suggesting that
whatever the mechanism of loss of episomes, it does not involve p53
(Fig. 5F). Furthermore, the reduction in E6 levels is not sufﬁcient to
adversely affect p53 targeting, implying that only a subset of E6 is
affected by loss of PDZ binding capacity.
To overcome the issue of the very low average copy number within
the populations that made Southern blot analysis very difﬁcult, the
experiment was repeated but instead of analyzing populations of
transfected cells, individual clones were isolated from the populations.
Of course it was not possible to meaningfully assess the levels of the
wild-type and E6ΔPBM proteins expressed from the genomes (as we
already knew that the copy numbers would be different, even at the
start of the cloning process). However, it was possible to assess the copyFig. 5. Low E6 expression associated with theΔPBMmutation correlates with the loss of
episomes in HPV positive cell populations. NIKS cells were co-transfected with a
plasmid that expresses GFP, and either wild-type HPV16 (16WT) or HPV16 genomes
containing the E6ΔPBM mutation (16E6ΔPBM). A) At 48 h post-transfection the cells
were harvested and the HPV genome-containing populations were enriched for using
FACS based on their GFP signal. Total cell extracts were obtained from the GFP positive
and negative populations, and Western blotted for E6, GFP, and as a loading control,
HSP70. B) RNA was extracted from the total cell population, and the number of E6
transcripts, relative to β-actin transcripts was assessed using qPCR. The experiment was
done in triplicate and the bar chart shows the mean level of transcripts+the standard
deviation. An unpaired T-test was used to compare the E6 transcript levels, p=0.328.
C) NIKS cells were transfected with 16WT or 16E6ΔPBM genomes, or control plasmid
(has E4 ORF but no eukaryotic origin of replication or promoter). At 4 days post-
transfection episomal DNA was extracted and levels of replication quantiﬁed by qPCR.
Four replicates were analyzed and the bar chart shows the mean level of relative
replication (as a percentage value)+the standard deviation. D) NIKS cells were co-
transfected with a blasticidin resistance plasmid and either the 16WT or 16E6ΔPBM
genomes and HPV-positive populations were selected with blasticidin. DNA was
extracted over the course of ten passages, and qPCR was used to assess the number of
HPV copies per cell (copy number). Bar charts show the mean copy number per cell+
the standard deviation of triplicate qPCR repeats and are representative of two repeat
experiments. E) DNA was analyzed by Southern blot, using either restriction enzymes
that do or do not cut HPV16 (Bam HI and Hind III respectively), and an HPV-positive
episomal NIKS cell line DNA as a positive control. The positions of linear, open circular
(OC) and supercoiled (SC) episomal genomes are indicated, as is the position of likely
integrated DNA (*). F) NIKS cells were co-transfected with a plasmid that expresses
GFP, and either 16WT or 16E6ΔPBM or a control plasmid pMV10. At 48 h post-
transfection the cells were harvested and transfected populations were enriched for
using FACS based on their GFP signal. Total cell extracts were obtained from the GFP
positive populations, and Western blotted for p53, and as a control, HSP70. The cells
were independently transfected twice and the bar chart shows the mean level of p53 in
the16E6ΔPBM population, normalized to the level in the 16WT population,±the range.
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genomes over time (Fig. 6). After producing the clonal lines we found
that whilst 70% of the 16WT clones were positive for HPV16 DNA, only
8% of the 16E6ΔPBM mutant clones contained genomes (Fig. 6A). This
suggests that the 16E6ΔPBM mutant genomes are less able to be
maintained in the cells than the wild-type genomes. In fact the
16E6ΔPBM clonal lines that were positive (2 out of 26), although
having copy numbers similar to the 16WT clones tested, were both
found to harbor integrated copies of HPV16 DNA (Fig. 6B). To conﬁrm
that the integration phenotype that we observed with the 16E6ΔPBM
genomewas speciﬁc to thismutant, andnot a result of ourmethodology,
we monitored the status of the wild-type genome over time (Fig. 6C).
The wild-type genomes were observed to be episomal irrespective of
the time-point analyzed. We have therefore no reason to believe that
the loss of the episomal phenotypewas a result of ourmethodology and
rather is speciﬁc to the 16E6ΔPBM genomes.
Discussion
The interaction of high-risk E6 proteins with PDZ domain-
containing proteins has been widely reported; however its role inFig. 6. The ΔPBM mutation is associated with a reduced ability to establish clonal HPV-
positive episomal cell lines. A) NIKS cells were co-transfected with a blasticidin
resistance plasmid and either the 16WT or 16E6ΔPBM genomes. The cells were grown
for 2 days then seeded at low density with blasticidin treatment to obtain clonal lines of
cells. DNA was extracted and qPCR was used to assess copy number. B) The DNA from
three clones each of 16WT and 16E6ΔPBM was cut with Hind III restriction enzyme
(does not cut HPV16 DNA) and Southern blotted. The positions of linear, open circular
(OC) and supercoiled (SC) episomal genomes are indicated. HPV-positive and -negative
NIKS DNAs were included as positive and negative controls respectively. C) DNA from
one of the 16WT clones was extracted over multiple passages, cut with Hind III and
analyzed by Southern blot.the viral life-cycle has not been extensively analyzed. Here we show
that, at the levels of E6 expressed from genomes, the interaction
results in a signiﬁcant stabilization of the E6 protein, which suggests
that at least one consequence of the association may be to ensure that
sufﬁcient levels of E6 are present in the cells. Even in a cancer cell line
in which the level of E6 is much higher, we observed a signiﬁcant
decrease in E6 levels when hScrib was knocked-down. It will be
interesting to see whether the same change in levels is observed if the
levels of Dlg or MAGI are knocked-down and whether the different
HPV E6 types are stabilized to different extents by particular PDZ
domain-containing proteins. The work also highlights the need for
caution when interpreting the result of mutating the E6 PBM, where
changes in phenotype may result from changes in E6 level rather than
direct effects of E6 on PDZ domain-containing proteins. It is alsoworth
noting that the particular mutation used is a 4 amino acid deletion of
the E6 carboxy terminus; whether more subtle point mutations
within the PBM will have a similar effect, remains to be determined.
It is interesting that a protein that E6 targets for degradation,
hScrib, (Nakagawa and Huibregtse, 2000), itself appears to stabilize
E6. This is however also the case for another of E6's targets, the
ubiquitin ligase E6AP (Kao et al., 2000; Tomaic et al., 2009). Thus the
interactions between E6 and its binding partners are complex and we
hypothesize that the exact outcomes depend on the levels, as well as
the modiﬁcations and localizations of the proteins, with different
cellular pools behaving in different ways. E6 is already known to
interact differently with PDZ proteins depending on which cellular
site they are located at and how they are modiﬁed (Massimi et al.,
2004; Massimi et al., 2006; Narayan et al., 2009). When expressed at
high level, e.g. in cancer cell lines, E6 appears to induce degradation of
PDZ domain-containing proteins, but this has not been reported for E6
expressed at levels typical of productive infections. Indeed in our own
experiments, the levels of hScrib appear the same in the GFP-sorted
populations that express wild-type or E6ΔPBM proteins as those in
control populations (data not shown). How a given PDZ domain-
interaction might stabilize E6 itself is currently unclear; however the
E6 PBM is a highly unstructured region, but this obtains a deﬁned
structure once in complexwith a speciﬁc PDZ domain (Charbonnier et
al., 2011; Nomine et al., 2006; Zhang et al., 2007), suggesting that this
may in turn contribute indirectly towards E6 stability. Now that
current Western blotting protocols can detect E6 protein expressed
from high-risk HPV genomes, future studies will be able to monitor
the level of E6 protein expressed. Ensuring adequate expression of any
E6 mutants may help elucidate the role of the different E6 activities,
localizations, and binding partners in E6 protein function.
One known function of E6 is that it is necessary for viral episomal
maintenance, as mutants lacking a functional E6 protein are unable to
persist within the cell (Park and Androphy 2002; Thomas, et al. 1999).
The precise activity of E6 that is necessary for this function is not yet
clear. Here,wehave shown thatmutantHPV16genomes that lack theE6
PBM are unable to persist episomally in NIKS cells and are found
integrated into the cellular DNA. In agreement with these results, a
study of HPV31 genomes containing E6 mutants that do not bind PDZ
domains showed that these genomes do not maintain at wild-type
levels and are often found integrated at later passages (Lee and Laimins
2004). Together these results suggest that loss of the PBM of E6 has a
dramatic effect on genome maintenance. The reduction in E6 levels
following loss of the E6 PBM might be expected to have additional
effects, and although HPV31 E6 protein levels were not established in
the study of Lee and Laimins (2004), the observed effects on cell growth
and morphological differentiation might be explained by the lack of
PDZ-mediated E6 stabilization. Lower levels of E6might also explain the
reduced epithelial hyperplasia observed in transgenicmice that express
a PDZ-binding mutant rather than wild-type E6 (Nguyen et al., 2003).
Of primary interest remains as towhy E6 is required for the episomal
maintenance of viral genomes. Our maintenance experiments do not
distinguish betweendirect effects of the E6ΔPBMmutation in preventing
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changing the E6 levels and therefore its effects on other cellular proteins.
Other activities of E6 including the degradation of p53 (Oh et al., 2004;
Park and Androphy, 2002; Thomas et al., 1999) and the degradation of
E6TP1 (Lee et al., 2007) have previously been implicated in episomal
maintenance. How these activities support maintenance is not under-
stood, although it has been suggested that p53maybe a suppressor of the
ampliﬁcational replication of HPV following infection (Lepik et al., 1998).
However it seems reasonable to hypothesize that a tight regulation of the
levels of E6 post-infection may be crucial for the establishment of a
replication-competent environment in thebasal cells. Our results suggest
that in the absence of a PBM, the levels of E6 are not stabilized, and this
mayhave implications for the abilityof E6 toaffect other cellular proteins.
However, the capacity of the mutant genomes to target p53 seems to be
unaffected, suggesting that only E6 found in conjunction with hScrib, or
in that particular cellular location is susceptible to enhanced degradation
when the PBM is deleted. This also suggests that the pool of E6 that is
stabilized byhScribmaynot be thatwhich is involved in p53 degradation
and this is supported by previous observations showing that the levels of
expression of an E6 mutant defective in PDZ recognition were still
sufﬁcient to degrade p53 (Foster et al., 1994).Wehave also observed that
genomes defective for p53 degradation do not maintain in NIKS cells;
however, their phenotype appears different from that of the 16E6ΔPBM
mutant genomes (data not shown). Taken together, these observations
suggest that E6 activities in addition to those on p53 are necessary to
facilitate episomal maintenance.
In addition to stabilizing E6, the interaction with some PDZ domain-
containing proteins and their resulting degradationmay also be directly
involved in genomemaintenance of the high-risk viruses. How thismay
come about is not clear. PDZ domain-containing proteins are signal
transducers, involved in cell-cycle progression and regulation of cell
polarity (Pim and Banks, 2010), and the disruption of these functions
may be necessary for creating a cellular environment that is conducive
to genome maintenance. A systematic knockdown of expression of
selected E6 PDZ targets in the context of the wild-type and mutant
genomes should help clarifywhich PDZ domain-containing proteins are
relevant for the in vivo stabilization and any further involvement of
theseproteins in genomemaintenance. It is interesting to note that low-
risk HPV, whose E6 proteins are not capable of binding to PDZ domain-
containing proteins, is not well maintained as episomes in cell culture
(our own observations and Oh et al., 2004). This may suggest that the
interaction between E6 proteins and PDZ domain-containing proteins is
important in allowing maintenance of HPV genomes under particular
conditions, such as in the proliferating basal cells present in lesions
induced by high-risk papillomaviruses.
Materials and methods
Routine cell culture
NIKS, an HPV-negative, spontaneously immortalized keratinocyte
cell line (Allen-Hoffmann et al., 2000), and anHPV16-positive episomal
NIKS line (Laurson et al., 2010)weremaintained at sub-conﬂuent levels
on γ-irradiated J2-3T3 feeder cells, as previously described (Lambert
et al., 2005). When required, cells were treated with 40 μM MG132,
50 μgml−1 cycloheximide or an equivalent volume of DMSO. HeLa cells
were maintained as previously described (Kranjec and Banks, 2010).
293T cells weremaintained in DMEM supplemented with 10% fetal calf
serum and 1% penicillin and streptomycin.
Plasmids
The pSPW12 plasmid (a kind gift from Prof. Margaret Stanley),
containing the HPV16 genomewasmutated to pSPW12E6ΔPBMusing
PfuUltra (Stratagene), and the forward and reverse primers, gcagat-
catcaagaacacgtagataaacccagctgtaatcatgcatgg and gcagctctgtgca-taactgtggtaactttgtggcgctctcctgtgggtcctgaaacattgc. The 16WT and
16E6ΔPBM genomes were excised from the Bam HI site in these
plasmids and recircularized as previously described (Lambert et al.,
2005). The pMV11E6 and pMV11E6ΔPBM plasmids were created by
sub-cloning the E6 ORFs from pSPW12 and pSPW12E6ΔPBMplasmids
into the Bam HI and Eco RI sites of pMV11 (using the forward primer
gctgggatccatgcaccaaaagagaactgcaatg, reverse primer aggcgaattctta-
cagctgggtttctctacgtgttc for wild-type E6 and aggcgaattcttacagctgggtt-
tatctacgtgttc for the E6ΔPBM mutant). The pMV10 plasmid that
expresses β-galactosidase and the plasmid that expresses HPV11 E6
have been previously described (Forrester et al., 1992; Glaunsinger
et al., 2000). Plasmids that express wild-type and mutant hScrib
(pCDNA:HA-hScrib and pCDNA:hScribΔPDZ), HA-Dlg (pGWI:HA-Dlg)
and FLAG-MAGI (pcDNA:FLAG-MAGI-1c) have been described previ-
ously (Gardiol et al., 1999; Glaunsinger et al., 2000; Nagasaka et al.,
2010). The prokaryotic pET-28 plasmid containing 16E1^E4 has been
described before (McIntosh et al., 2008).
Transfections
For transient transfections of NIKS cells, 1 μg of DNA was
transfected into the cells using Effectene (Qiagen), according to the
manufacturer's instructions. For stable transfections of NIKS cells,
5×105 cells were seeded over 1×105 J2-3T3 cells per well of a six well
plate the day before the transfection. The cells were transfected with
800 ng of recircularized HPV16 DNA and 200 ng of the blasticidin-
resistant plasmid pcDNA6 (Invitrogen) using Effectene. The next day
the cells were seeded onto 10 cm plates over blasticidin-resistant
feeders and the day after were treated with 8 μg ml−1 blasticidin. The
blasticidin treatment was carried out for 4 days, at which point the
surviving cells were transferred to new feeders in the absence of
blasticidin and designated passage one (P1). For the cloning
experiments, the cells were transfected as above, grown for 2 days
and then plated at low density on blasticidin-resistant feeders. The
cells were treated with blasticidin as above and were then grown to
the stage of visible colonies thatwere transferred ﬁrst to a 6well plate,
then to a 10 cm plate, at which point their DNA was analyzed for the
presence of HPV16 episomes. For siRNA delivery, cells were
transfected as previously described (Kranjec and Banks, 2010) but
using SCRIB ON-TARGETplus SMARTpool siRNA, and harvested at 72 h
post transfection.
Southern blots, qPCR and RT-qPCR
Total DNA was extracted using the QIAamp DNAMini Kit (Qiagen)
and quantiﬁed on a NanoDrop ND-1000 spectrophotometer. Total
RNA was extracted using the QIAshredder and RNeasy Mini kits
(Qiagen), and the DNA-free kit (Ambion). The SuperScript II Reverse
Transcription Kit (Invitrogen) and random primers were used to
generate cDNA. Absolute QPCR SYBR Green ROX mix was used to
quantify the numbers of HPV genomes (using E4 primers, and as a
control, GAPDH primers), or the levels of E6 transcript cDNA (using E6
primers, and as a control, β-actin primers) on a Prism 7000 Sequence
Detection System (Applied Biosystems). The genomic DNA was also
separated on 1% agarose gels, transferred to Immobilon-NY+ Transfer
Membrane (Millipore) and Southern blotted using 32P-dCTP labeled
pSPW12 plasmid as a probe. Southern blots were adjusted for
brightness and contrast using Photoshop. Regions of gels that have
been adjusted for brightness and contrast to different levels are
separated by a white band and show only relative position, not
relative intensity of bands.
Transient replication assays
The method for the transient replication assays was modiﬁed from
a previously described protocol (Taylor and Morgan, 2003). Brieﬂy,
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following day transfected with equimolar amounts of either recircu-
larized wild-type or mutant HPV16 DNA (1 μg) or pET-28 plasmid
carrying the E1^E4 cDNA (700 ng, plus 300 ng of pMV11 plasmid).
Four days post-transfection the cells were trypsinized and resus-
pended in 0.5 ml PBS at a concentration of 1.8×106 cells/ml. Episomal
DNA was extracted as previously described (Hoffmann et al., 2006).
Following ethanol precipitation, 3 μl of DNA was digested with Dpn I
for 3 h, and then exonuclease III for 30 min, followed by enzyme
inactivation at 70 °C for 30 min. Another 3 μl of DNAwas treated in the
same way, but without any enzyme, and these represent the
undigested samples. Amounts of HPV16 DNA were measured in
both Dpn I-digested and undigested samples by qPCR, using primers
against the E4 ORF of HPV16, and the former was divided by the latter
to give a relative value for replication.
SDS–PAGE and Western blotting
To obtain total cell extracts from NIKS cells, 25 U of benzonase was
added to the cell pellet, which was then lysed at 95 °C for 7 min in
150 μl of protein extraction buffer (6% SDS, 1% triton, 0.5% sodium
deoxycholate, 150 mMNaCl, 0.005 mM EDTA, 50 mM Tris–HCl pH 8.0,
supplemented with Protease Inhibitor Cocktail (Sigma)). The soluble
protein concentration was assessed using the DC Protein Assay Kit
(Bio-Rad), then 100 mM DTT and loading dye were added. HeLa cells
were lysed as previously described (Kranjec and Banks, 2010).
Equivalent amounts of protein were separated on SDS–polyacryl-
amide gels, and transferred to 0.2 or 0.4 μm PVDF membrane
(Millipore). 16E6 was detected with antibodies 2E-3F8 or 1E-6F4
(Euromedex), 18E6 with an anti-18E6 antibody (kindly provided by
Arbor Vita Corporation), HSP70 with W-27 (Santa Cruz), β-gal with
ab616 (Abcam), hScrib with C-20 (Santa Cruz Biotechnology), HA-tag
with H6908 (Sigma), FLAG-tag with 2368 (Cell Signalling), histone 2B
with 07-371 (Upstate), α-actinin with H-2 (Santa Cruz Biotechnol-
ogy), GFP with sc-9996 (Santa Cruz) then anti-mouse IgG-HRP
NA931V (GE Healthcare), or anti-rabbit IgG-HRP NA934V (GE
Healthcare) or anti-goat HRP P0160 (DAKO), followed by detection
using either the ECL Western Blotting Detection kit (GE Healthcare),
the Immobilon Western Chemiluminescent HRP kit (Millipore) or the
ECL Advance kit (GE Healthcare).Western blots were quantiﬁed using
ImageJ and adjusted for brightness and contrast in Photoshop.
Fluorescent activated cell sorting (FACS)
The day before transfection, 5.5×105 NIKS were seeded over
1×105 J2-3T3 cells per well of a six well plate. These were transfected
with 800 ng of recircularized HPV16 DNA and 200 ng of pcieGFP
plasmid. 25 wells were transfected with each recircularized DNA,
16WT and 16E6ΔPBM or with pMV10 plasmid as a control. Two days
post-transfection, the cells were washed with 1× DPBS (PAA) and
then detached from the plate using Accutase (Millipore). The cells
were pelleted and resuspended in 1.5 ml of Dulbecco's PBS containing
0.5% FBS and 5 mM EDTA. Immediately before sorting, the cells were
passed through a 40 μm cell strainer (BD Biosciences). The cells were
sorted on a Becton Dickinson FACS ARIA II Cell Sorter.
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